Berberine exerts an anti-inflammatory role in ocular Behcet's disease

Yang,Yan; Wang,Qin; Xie,Manyun; Liu,Ping; Qi,Xin; Liu,Xiao; Li,Zhuo

doi:10.3892/mmr.2016.5980

Berberine exerts an anti-inflammatory role in ocular Behcet's disease

Authors:
- Yan Yang
- Qin Wang
- Manyun Xie
- Ping Liu
- Xin Qi
- Xiao Liu
- Zhuo Li
View Affiliations

Affiliations: Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410010, P.R. China
Published online on: December 5, 2016 https://doi.org/10.3892/mmr.2016.5980
Pages: 97-102
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Behcet's disease is a multi‑system inflammatory disorder, and ocular Behcet's disease (OBD) is one of the most common causes of uveitis in China. A number of studies have indicated that Th17 cells, a subset of interleukin-17 (IL-17)-producing CD4+ T‑helper cells, serve important roles in the pathogenesis of OBD. Berberine (BBR) is an isoquinoline derivative alkaloid isolated from Chinese herbs, and has been used traditionally for the treatment of gastrointestinal disorders. The aim of the present study was to investigate the effect of BBR on Th17 cell proliferation and cytokine secretion, and the expression and activation of the signal transducer and activator of transcription 3 (STAT3) transcription factor in OBD in vitro. Blood samples were obtained from healthy controls and patients with active ocular Behcet's disease. Peripheral blood mononuclear cells (PBMCs) or CD4+ T cells were cultured for three days with or without BBR and in the presence of anti‑CD3 and anti‑CD28 antibodies. IL‑17 expression in cell sample supernatants was determined by enzyme‑linked immunosorbent assay, and cell viability was measured using the Cell Counting kit‑8 assay. The number of CD4+IL‑17+ cells and the expression level of phosphorylated (p)‑STAT3 in CD4+ T cells was determined using flow cytometry analysis. The expression of IL‑17 was increased in patients with active OBD following the activation of PBMCs and CD4+ T cells with anti‑CD3 and anti‑CD28 antibodies when compared with healthy controls. However, no significant difference in cell viability following exposure to BBR was observed in PBMCs derived from healthy controls or patients with OBD. Following incubation with BBR, the expression of IL‑17 was reduced and the number of CD4+IL‑17+ cells was decreased in patients with active OBD and healthy controls. Furthermore, the expression of p-STAT3 was significantly decreased in the presence of BBR in healthy controls. In conclusion, the results of the present study demonstrate that BBR may suppress the Th17 response in patients with OBD by reducing STAT3 phosphorylation. BBR may be a potential therapeutic agent for the treatment of OBD.

View Figures

View References

1	Ye M, Fu S, Pi R and He F: Neuropharmacological and pharmacokinetic properties of berberine: A review of recent research. J Pharm Pharmacol. 61:831–837. 2009. View Article : Google Scholar : PubMed/NCBI
2	Song YC, Lee Y, Kim HM, Hyun MY, Lim YY, Song KY and Kim BJ: Berberine regulates melanin synthesis by activating PI3K/AKT, ERK and GSK3β in B16F10 melanoma cells. Int J Mol Med. 35:1011–1016. 2015.PubMed/NCBI
3	Saha P, Bhattacharjee S, Sarkar A, Manna A, Majumder S and Chatterjee M: Berberine chloride mediates its anti-leishmanial activity via differential regulation of the mitogen activated protein kinase pathway in macrophages. PLoS One. 6:e184672011. View Article : Google Scholar : PubMed/NCBI
4	Chi L, Peng L, Pan N, Hu X and Zhang Y: The anti-atherogenic effects of berberine on foam cell formation are mediated through the upregulation of sirtuin 1. Int J Mol Med. 34:1087–1093. 2014.PubMed/NCBI
5	Hu Z, Jiao Q, Ding J, Liu F, Liu R, Shan L, Zeng H, Zhang J and Zhang W: Berberine induces dendritic cell apoptosis and has therapeutic potential for rheumatoid arthritis. Arthritis Rheum. 63:949–959. 2011. View Article : Google Scholar : PubMed/NCBI
6	Cui G, Qin X, Zhang Y, Gong Z, Ge B and Zang YQ: Berberine differentially modulates the activities of ERK, p38 MAPK, and JNK to suppress Th17 and Th1 T cell differentiation in type 1 diabetic mice. J Biol Chem. 284:28420–28429. 2009. View Article : Google Scholar : PubMed/NCBI
7	Qin X, Guo BT, Wan B, Fang L, Lu L, Wu L, Zang YQ and Zhang JZ: Regulation of Th1 and Th17 cell differentiation and amelioration of experimental autoimmune encephalomyelitis by natural product compound berberine. J Immunol. 185:1855–1863. 2010. View Article : Google Scholar : PubMed/NCBI
8	Yang Y, Qi J, Wang Q, Du L, Zhou Y, Yu H, Kijlstra A and Yang P: Berberine suppresses Th17 and dendritic cell responses. Invest Ophthalmol Vis Sci. 54:2516–2522. 2013. View Article : Google Scholar : PubMed/NCBI
9	Yang P, Fang W, Meng Q, Ren Y, Xing L and Kijlstra A: Clinical features of chinese patients with Behçet's disease. Ophthalmology. 115:312–318. 2008. View Article : Google Scholar : PubMed/NCBI
10	Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, Gery I, Lee YS and Egwuagu CE: TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med. 13:711–718. 2007. View Article : Google Scholar : PubMed/NCBI
11	Chi W, Yang P, Li B, Wu C, Jin H, Zhu X, Chen L, Zhou H, Huang X and Kijlstra A: IL-23 promotes CD4⁺ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol. 119:1218–1224. 2007. View Article : Google Scholar : PubMed/NCBI
12	Peng Y, Han G, Shao H, Wang Y, Kaplan HJ and Sun D: Characterization of IL-17⁺ interphotoreceptor retinoid-binding protein-specific T cells in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 48:4153–4161. 2007. View Article : Google Scholar : PubMed/NCBI
13	Luger D, Silver PB, Tang J, Cua D, Chen Z, Iwakura Y, Bowman EP, Sgambellone NM, Chan CC and Caspi RR: Either a Th17 or a Th1 effector response can drive autoimmunity: Conditions of disease induction affect dominant effector category. J Exp Med. 205:799–810. 2008. View Article : Google Scholar : PubMed/NCBI
14	Liu X, Yang P, Lin X, Ren X, Zhou H, Huang X, Chi W, Kijlstra A and Chen L: Inhibitory effect of Cyclosporin A and corticosteroids on the production of IFN-gamma and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome. Clin Immunol. 131:333–342. 2009. View Article : Google Scholar : PubMed/NCBI
15	Mathur AN, Chang HC, Zisoulis DG, Stritesky GL, Yu Q, O'Malley JT, Kapur R, Levy DE, Kansas GS and Kaplan MH: Stat3 and Stat4 direct development of IL-17-secreting Th cells. J Immunol. 178:4901–4907. 2007. View Article : Google Scholar : PubMed/NCBI
16	Tulunay A, Dozmorov MG, Ture-Ozdemir F, Yilmaz V, Eksioglu-Demiralp E, Alibaz-Oner F, Ozen G, Wren JD, Saruhan-Direskeneli G, Sawalha AH and Direskeneli H: Activation of the JAK/STAT pathway in Behcet's disease. Genes Immun. 16:170–175. 2014.PubMed/NCBI
17	Qi J, Yang Y, Hou S, Qiao Y, Wang Q, Yu H, Zhang Q, Cai T, Kijlstra A and Yang P: Increased Notch pathway activation in Behçet's disease. Rheumatology (Oxford). 53:810–820. 2014. View Article : Google Scholar : PubMed/NCBI
18	Criteria for diagnosis of Behçet's disease, . International Study Group for Behçet's Disease. Lancet. 335:1078–1080. 1990.PubMed/NCBI
19	Rickham PP: Human experimentation. Code of ethics of the world medical association. Declaration of Helsinki. Br Med J. 2:1771964. View Article : Google Scholar : PubMed/NCBI
20	Ma X, Jiang Y, Wu A, Chen X, Pi R, Liu M and Liu Y: Berberine attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice. PLoS One. 5:e134892010. View Article : Google Scholar : PubMed/NCBI
21	Marinova EK, Nikolova DB, Popova DN, Gallacher GB and Ivanovska ND: Suppression of experimental autoimmune tubulointerstitial nephritis in BALB/c mice by berberine. Immunopharmacology. 48:9–16. 2000. View Article : Google Scholar : PubMed/NCBI
22	Gupta SK, Agarwal R, Srivastava S, Agarwal P, Agrawal SS, Saxena R and Galpalli N: The anti-inflammatory effects of Curcuma longa and Berberis aristata in endotoxin-induced uveitis in rabbits. Invest Ophthalmol Vis Sci. 49:4036–4040. 2008. View Article : Google Scholar : PubMed/NCBI
23	Na SY, Park MJ, Park S and Lee ES: Up-regulation of Th17 and related cytokines in Behçet's disease corresponding to disease activity. Clin Exp Rheumatol. 31(3): Suppl 77. 32–40. 2013.PubMed/NCBI
24	Chi W, Yang P, Zhu X, Wang Y, Chen L, Huang X and Liu X: Production of interleukin-17 in Behcet's disease is inhibited by cyclosporin A. Mol Vis. 16:880–886. 2010.PubMed/NCBI
25	Hedegaard CJ, Krakauer M, Bendtzen K, Sorensen PS, Sellebjerg F and Nielsen CH: The effect of beta-interferon therapy on myelin basic protein-elicited CD4⁺ T cell proliferation and cytokine production in multiple sclerosis. Clin Immunol. 129:80–89. 2008. View Article : Google Scholar : PubMed/NCBI
26	Xu L, Liu Y and He X: Inhibitory effects of berberine on the activation and cell cycle progression of human peripheral lymphocytes. Cell Mol Immunol. 2:295–300. 2005.PubMed/NCBI
27	Jiang XW, Zhang Y, Zhu YL, Zhang H, Lu K, Li FF and Peng HY: Effects of berberine gelatin on recurrent aphthous stomatitis: A randomized, placebo-controlled, double-blind trial in a Chinese cohort. Oral Surg Oral Med Oral Pathol Oral Radiol. 115:212–217. 2013. View Article : Google Scholar : PubMed/NCBI
28	Pang B, Zhao LH, Zhou Q, Zhao TY, Wang H, Gu CJ and Tong XL: Application of berberine on treating type 2 diabetes mellitus. Int J Endocrinol. 2015:9057492015.PubMed/NCBI